A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.
Rimonabant has been studied across 24 research domains including 🔥 Metabolic, 🌤️ Mood & Depression, 🧬 Hormones, 🧘 Stress & Anxiety, ❤️ Cardiovascular. The primary research focus is 🔥 Metabolic with 48% of studies addressing this area.
The following compounds share molecular targets with Rimonabant, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Rimonabant is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.